Canaccord raised the firm’s price target on Regulus to $12 from $9 and keeps a Buy rating on the shares. The firm noted the company delivered positve clinical data from cohort 1 of the Ph1b study of RGLS8429 in ADPKD this morning delivered everything it needed to, there was nothing of note on the safety/ tolerability side, and biomarker data show clear treatment effect.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGLS:
